Reply
Long H. Nguyen, Mindie Nguyen – 16 March 2012
Not all types of acute kidney injury are equal in the setting of liver transplantation
Milind Junghare, Hassan N. Ibrahim – 16 March 2012
Immediate intraportal transplantation of human bone marrow mesenchymal stem cells prevents death from fulminant hepatic failure in pigs
Jun Li, Liyuan Zhang, Jiaojiao Xin, Longyan Jiang, Jun Li, Ting Zhang, Linfeng Jin, Jianzhou Li, Pengcheng Zhou, Shaorui Hao, Hongcui Cao, Lanjuan Li – 16 March 2012 – The effectiveness of human bone marrow mesenchymal stem cell (hBMSC) transplantation to treat acute and chronic liver injury has been demonstrated in animal models and in a few nonrandomized clinical trials. However, no studies have investigated hBMSC transplantation in the treatment of fulminant hepatic failure (FHF), especially in large animal (pig) models.
Hemodynamics‐compliant reconstruction of the right hepatic vein for adult living donor liver transplantation with a right liver graft
Shin Hwang, Tae‐Yong Ha, Chul‐Soo Ahn, Deok‐Bog Moon, Gi‐Won Song, Ki‐Hun Kim, Dong‐Hwan Jung, Gil‐Chun Park, Kyu‐Bo Sung, Gi‐Young Ko, Kyoung Won Kim, Byungchul Cho, Jung‐Man Namgoong, Sung‐Won Jung, Sam‐Youl Yoon, Chun‐Soo Park, Yo‐Han Park, Hyeong‐Woo Park, Hyo‐Jun Lee, Sung‐Gyu Lee – 16 March 2012 – Secure reconstruction of the right hepatic vein (RHV) is essential for the successful implantation of a right liver graft during living donor liver transplantation (LDLT).
Does reference value of “Normal Liver Stiffness” using fibroscan have a regional variation?
Ramesh Kumar, Manoj Kumar Sharma, Shiv Kumar Sarin – 15 March 2012
Human mesenchymal stem cells are recruited to injured liver in a β1‐integrin and CD44 dependent manner
Victoria Aldridge, Abhilok Garg, Nicholas Davies, David C. Bartlett, Janine Youster, Heather Beard, Dean P. Kavanagh, Neena Kalia, Jon Frampton, Patricia F. Lalor, Philip N. Newsome – 15 March 2012 – Human bone marrow mesenchymal stem cells (hMSCs) have shown benefit in clinical trials of patients with liver disease. Efficient delivery of cells to target organs is critical to improving their effectiveness. This requires an understanding of the mechanisms governing cellular engraftment into the liver.
Beyond reasonable doubt: Who is the culprit in lipotoxicity in NAFLD/NASH?
Gavin E. Arteel – 15 March 2012
Reply: Does reference value of “Normal Liver Stiffness” using fibroscan have a regional variation?
Abhijit Chowdhury, Kausik Das – 15 March 2012
Structural analysis of oval‐cell–mediated liver regeneration in rats
Katalin Dezső, Veronika Papp, Edina Bugyik, Hargita Hegyesi, Géza Sáfrány, Csaba Bödör, Péter Nagy, Sándor Paku – 15 March 2012 – We have analyzed the architectural aspects of progenitor‐cell–driven regenerative growth in rat liver by applying the 2‐acetaminofluorene/partial hepatectomy experimental model. The regeneration is initiated by the proliferation of so‐called oval cells. The oval cells at the proximal tips of the ductules have a more differentiated phenotype and higher proliferative rate.
Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy
Young Mok Lee, Hyun Sik Jun, Chi‐Jiunn Pan, Su Ru Lin, Lane H. Wilson, Brian C. Mansfield, Janice Y. Chou – 15 March 2012 – Glycogen storage disease type Ia (GSD‐Ia), which is characterized by impaired glucose homeostasis and chronic risk of hepatocellular adenoma (HCA), is caused by deficiencies in the endoplasmic reticulum (ER)‐associated glucose‐6‐phosphatase‐α (G6Pase‐α or G6PC) that hydrolyzes glucose‐6‐phosphate (G6P) to glucose. G6Pase‐α activity depends on the G6P transporter (G6PT) that translocates G6P from the cytoplasm into the ER lumen.